about
Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadFundamentals of aerosol therapy in critical careSolubility prediction of anthracene in mixed solvents using a minimum number of experimental data.Effects of terbutaline in combination with mannitol on mucociliary clearance.Aerosol deposition and clearance measurement: a novel technique using dynamic SPET.Use of solid corrugated particles to enhance powder aerosol performance.Inhaler Technique in Asthma: How Does It Relate to Patients' Preferences and Attitudes Toward Their Inhalers?Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length.Inhaled mannitol shifts exhaled nitric oxide in opposite directions in asthmatics and healthy subjects.Focused-ion-beam milling: a novel approach to probing the interior of particles used for inhalation aerosols.Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers.Micro-particle corrugation, adhesion and inhalation aerosol efficiency.Scanning white-light interferometry as a novel technique to quantify the surface roughness of micron-sized particles for inhalation.Lactose composite carriers for respiratory delivery.Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems.Impact angles as an alternative way to improve aerosolisation of powders for inhalation?Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance.Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems.Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems.Advances in device and formulation technologies for pulmonary drug delivery.Constant size, variable density aerosol particles by ultrasonic spray freeze drying.Does the United States Pharmacopeia throat introduce de-agglomeration of carrier-free powder from inhalers?Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance.A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.The role of particle properties in pharmaceutical powder inhalation formulations.The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers.Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies.Novel alternative methods for the delivery of drugs for the treatment of asthma.Attachment of micro- and nano-particles on tipless cantilevers for colloidal probe microscopy.Quantitative and qualitative examination of particle-particle interactions using colloidal probe nanoscopyMurine pharmacokinetics of rifapentine delivered as an inhalable dry powder.Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers.L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.Monitoring the Inhalation Flow Rate of Nebulized Aerosols Using an Ultrasonic Flow Meter: In Vitro Assessment.De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.SPECT Imaging for Radioaerosol Deposition and Clearance Studies.Dry powder aerosol delivery systems: current and future research directions.Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins.
P50
Q26822988-F95B9104-19EF-437E-9594-1ADC2DF6DE3CQ28068836-633E5F07-5937-4176-9499-B5C365CC82A4Q30671332-576EA9F6-8306-4540-9251-97F21534266AQ30721561-55C816D4-E8FE-4E0D-BF23-49D6EEBDF01BQ30729127-3E71256F-893E-47B2-A3C0-06BDED96A9F0Q30785424-53AD5D80-547B-49BE-B013-7D0CE08541FDQ30836841-E38911D4-C22E-41C1-A7E8-B2D33FF8DC5BQ31115703-78D62355-4AAF-4EC3-B970-0A076AD47402Q31867127-D0EFB4E8-C179-4EEB-AEE9-C5BD856B294FQ33280894-362B3B03-A799-4C9B-905B-526950CDC33CQ33300875-5782BA1F-AA87-4742-B398-CCABE7A5F4F6Q33347335-1D536D96-A0FD-41FE-B51D-D104A037079FQ33365125-5B93D076-2B80-4F75-AC10-718D45ED2C19Q33385175-DE4C0AED-079B-4FFF-92D7-549624FBEF25Q33549994-70C9BAD0-72DB-45EA-A479-D8F54A438D44Q33550410-97F2C3A9-90D0-49BE-8832-9AD9FE726B3EQ33628256-8D5FEAE9-FFFC-4E1F-B1E6-BBF3C8842FFBQ33809597-C42DAB29-F3E9-44C8-996B-5BCBF953EA07Q33832559-8A8AA839-0716-4BB2-A192-E62D559398A3Q33939905-4D780A30-1681-4B0E-B00A-FD82F0A95124Q33962567-F8AA5B8C-B57F-429C-A6C9-18AD4204079FQ34155627-5C7718C1-8FAF-4CB6-A6C8-4A87E99BBFA2Q34156985-D030C3A4-3C95-4B57-A92C-B0E3C5A46B81Q34186206-9BC3FA12-87E2-4523-8C50-E16DC63D842AQ34415443-06E325DD-E47B-4FCD-BBE0-AECD9B51F5B5Q34978061-8DAC6D53-57C0-4D50-A8D5-FE234339BA1EQ34978811-F8B7F459-4DA1-441A-A964-D68BD07BB010Q35006621-78F4F3FD-4A5E-481E-9C1D-68D61C960603Q35162130-8112FE54-88A1-4278-8F06-25BEEB5277B4Q35169746-AC706016-640A-47DA-9723-2E6D78659DE4Q35174594-3E6C92F8-744D-427C-8A09-33CADA6E82B7Q35216550-BEE8DA2D-88D3-46F9-AEAC-50D9928B3CD0Q35537054-393F04B2-BAA1-47AB-8316-62EE08E35FA6Q35896882-37862424-5D08-4AEC-82A2-A8709B3A126EQ35955030-9624665D-9275-423A-9BCE-AAF3D72BF24DQ36193844-6CE0D1CB-6A93-455B-B726-66D6788A9DC1Q36232490-C1CB9CAC-60DB-4E44-92C2-9C6DBF5129E6Q36427274-F80C3DFE-8D87-4525-AC8B-792B7127AA1BQ36427279-8ABDBA97-E96E-4C55-86B6-C7CF4D79FFBFQ36455352-29BF1E33-A7D6-4595-9B60-391E72BA8DF2
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Hak-Kim Chan
@ast
Hak-Kim Chan
@en
Hak-Kim Chan
@es
Hak-Kim Chan
@nl
Hak-Kim Chan
@sl
type
label
Hak-Kim Chan
@ast
Hak-Kim Chan
@en
Hak-Kim Chan
@es
Hak-Kim Chan
@nl
Hak-Kim Chan
@sl
altLabel
Hak K. Chan
@en
Hak-Kim Chan
@en
Hakkim Chan
@en
Kim Chan
@en
prefLabel
Hak-Kim Chan
@ast
Hak-Kim Chan
@en
Hak-Kim Chan
@es
Hak-Kim Chan
@nl
Hak-Kim Chan
@sl
P108
P244
P1053
O-9264-2017
P106
P1153
7403402677
P21
P214
43146937715113831505
P244
n2016185603
P31
P3829
P496
0000-0002-7054-3137
P569
2000-01-01T00:00:00Z
P7859
lccn-n2016185603